Wells Fargo & Company Sqz Biotechnologies CO Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.27 - $0.68 $1 - $4	6 Added 4.48%	140 $0
Q1 2023 May 12, 2023	BUY	$0.53 - $0.87 $1 - $1	2 Added 1.52%	134 $0
Q4 2022 Feb 13, 2023	BUY	$0.67 - $2.85 $2 - $11	4 Added 3.13%	132 $0
Q3 2022 Nov 14, 2022	BUY	$2.16 - $3.48 $8 - $13	4 Added 3.23%	128 $0
Q2 2022 Aug 12, 2022	SELL	$2.77 - $5.0 $58,940 - $106,390	-21,278 Reduced 99.42%	124 $0
Q1 2022 May 16, 2022	SELL	$4.01 - $10.42 $39,502 - $102,647	-9,851 Reduced 31.52%	21,402 $103,000
Q4 2021 Feb 14, 2022	SELL	$8.93 - $14.85 $198,585 - $330,234	-22,238 Reduced 41.57%	31,253 $279,000
Q3 2021 Nov 15, 2021	BUY	$11.46 - $15.77 $572,828 - $788,263	49,985 Added 1425.7%	53,491 $772,000
Q2 2021 Aug 16, 2021	SELL	$11.32 - $14.45 $7,120 - $9,089	-629 Reduced 15.21%	3,506 $51,000
Q1 2021 May 13, 2021	BUY	$12.07 - $29.9 $21,931 - $54,328	1,817 Added 78.39%	4,135 $56,000
Q4 2020 Feb 09, 2021	BUY	$13.25 - $34.58 $30,713 - $80,156	2,318 New	2,318 $67,000

1.47M

Ticker SQZ
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,248,600
Market Cap $1.46M
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.